Outcomes Among Patients Receiving Watchman LAAO vs Antiplatelet Therapy

BACKGROUND: Although Watchman left atrial appendage occlusion (LAAO) was approved for patients with atrial fibrillation who can tolerate short term anticoagulation, many patients are poor candidates for any duration of anticoagulation. OBJECTIVES: The objective of the study was to compare 1-year outcomes among patients receiving Watchman LAAO vs antiplatelet monotherapy. METHODS: We performed an overlap weighted observational comparative effectiveness analysis of postdischarge outcomes among Medicare beneficiaries in the Get With The Guidelines-AFIB Registry who received LAAO or antiplatelet therapy. Cox Regression was used for all-cause mortality and cause-specific hazard models were used for nonfatal outcomes. A win ratio was calculated with the following endpoint hierarchy: 1) all-cause death; 2) stroke, systemic embolism, or transient ischemic attack (TIA); 3) major bleeding (excluding gastrointestinal bleeding); and 4) gastrointestinal bleeding. RESULTS: -VASC score 5). Through the first 45 days, the adjusted risk of stroke, TIA or systemic embolism, major bleeding, or death was lower among patients who received LAAO (HR: 0.26; CI: 0.17-0.41; P < 0.001). Between 46 days and 1 year, the risk for the composite outcome was lower among patients who received LAAO (HR: 0.61; CI: 0.48-0.78; P < 0.001). The win ratio at 1 year was 2.71 (95% CI: 1.92-3.83; P < 0.0001), indicating significantly better outcomes among LAAO patients. CONCLUSIONS: Among patients with atrial fibrillation, treatment with LAAO was associated with a lower risk of stroke, TIA or systemic embolism, major bleeding, or death compared to antiplatelet therapy.

Authors

Institutions

Publication Details

Journal
JACC Advances
Published
2026-11-18
DOI
https://doi.org/10.1016/j.jacadv.2026.103458
Primary Topic
Atrial Fibrillation Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Outcomes Among Patients Receiving Watchman LAAO vs Antiplatelet Therapy

Daniel J. Friedman, Iyanuoluwa Ayodele, Brooke Alhanti, Jonathan Paul Piccini et al.
2 links
JACC Advances
Atrial Fibrillation Management and Outcomes
article

Outcomes Among Patients Receiving Watchman LAAO vs Antiplatelet Therapy

Daniel J. Friedman, Iyanuoluwa Ayodele, Brooke Alhanti, Jonathan Paul Piccini, José A. Joglar, William R. Lewis, Kenneth A. Ellenbogen, Gregg C. Fonarow, Anthony P. Kent, KEVIN P. JACKSON, Andrea M. Russo, DaJuanicia Holmes, Sreek Vemulapali
article en

Abstract

BACKGROUND: Although Watchman left atrial appendage occlusion (LAAO) was approved for patients with atrial fibrillation who can tolerate short term anticoagulation, many patients are poor candidates for any duration of anticoagulation. OBJECTIVES: The objective of the study was to compare 1-year outcomes among patients receiving Watchman LAAO vs antiplatelet monotherapy. METHODS: We performed an overlap weighted observational comparative effectiveness analysis of postdischarge outcomes among Medicare beneficiaries in the Get With The Guidelines-AFIB Registry who received LAAO or antiplatelet therapy. Cox Regression was used for all-cause mortality and cause-specific hazard models were used for nonfatal outcomes. A win ratio was calculated with the following endpoint hierarchy: 1) all-cause death; 2) stroke, systemic embolism, or transient ischemic attack (TIA); 3) major bleeding (excluding gastrointestinal bleeding); and 4) gastrointestinal bleeding. RESULTS: -VASC score 5). Through the first 45 days, the adjusted risk of stroke, TIA or systemic embolism, major bleeding, or death was lower among patients who received LAAO (HR: 0.26; CI: 0.17-0.41; P < 0.001). Between 46 days and 1 year, the risk for the composite outcome was lower among patients who received LAAO (HR: 0.61; CI: 0.48-0.78; P < 0.001). The win ratio at 1 year was 2.71 (95% CI: 1.92-3.83; P < 0.0001), indicating significantly better outcomes among LAAO patients. CONCLUSIONS: Among patients with atrial fibrillation, treatment with LAAO was associated with a lower risk of stroke, TIA or systemic embolism, major bleeding, or death compared to antiplatelet therapy.

JACC AdvancesVol. 5(12)
Medical University of South Carolina (US), Duke University (US), Virginia Commonwealth University (US), Ronald Reagan UCLA Medical Center (US), Cooper Medical School of Rowan University (US), Duke University Hospital (US), Duke Clinical Research Institute (US), Case Western Reserve University (US), Virginia Commonwealth University Medical Center (US), The University of Texas Southwestern Medical Center (US)
Boston Scientific Corporation
Good health and well-being
Atrial Fibrillation Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon